ReviewInternational journal of molecular sciences2022
Substance P, A Promising Therapeutic Target in Musculoskeletal Disorders.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Neuroimmune Regulation in Posttraumatic Bone Repair: From Inflammatory Transition to Neurovascular Coupling and Functional Recovery.Journal of cellular physiology · 2026Review
- From the Perspective of the Peripheral Sensory Nervous System: The Role of Vitamin D in Neurogenic Inflammatory Skin Disorders.Acta physiologica (Oxford, England) · 2026Review
- Neurogenic heterotopic ossification: from molecular mechanisms to clinical treatment.Journal of orthopaedic translation · 2026Review
- Production and characterization of rNGFSP: a recombinant fusion immunogen eliciting dual anti-NGF and anti-Substance P therapeutic antibodies for Degenerative Joint Disease.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- Structural and Molecular Effects of Dextrose on Cartilage: A Scoping Review.Current rheumatology reviews · 2026Article
- Observational
- Exercise-Dependent effects of substance P deficiency on joint degeneration and inflammation in a surgical mouse model of osteoarthritis.Arthritis research & therapy · 2025Article
- Intraarticular resiniferatoxin, a potent TRPV1 agonist, for treatment of osteoarthritic pain.Pain management · 2025Review
- Recent Advances in the Diagnosis and Management of Pediatric Orthopedic Disorders: A Comprehensive Review.Cureus · 2025Review
- Synovial Fluid Extracellular Vesicles from Patients with Severe Osteoarthritis Differentially Promote a Pro-Catabolic, Inflammatory Chondrocyte Phenotype.Biomolecules · 2025Article
- Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database.Scientific reports · 2024Article
- Review
- Potentiation of Collagen Deposition by the Combination of Substance P with Transforming Growth Factor Beta in Rat Skin Fibroblasts.International journal of molecular sciences · 2024Article
- Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database.Frontiers in pharmacology · 2024Article
- Inflammation and Organ Injury the Role of Substance P and Its Receptors.International journal of molecular sciences · 2023Review
- Substance P-A neuropeptide regulator of periodontal disease pathogenesis and potential novel therapeutic entity: A narrative review.Journal of Indian Society of PeriodontologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
A large number of studies have focused on the role of substance P (SP) and the neurokinin-1 receptor (NK1R) in the pathogenesis of a variety of medical conditions. This review provides an overview of the role of the SP-NK1R pathway in the pathogenesis of musculoskeletal disorders and the evidence for its role as a therapeutic target for these disorders, which are major public health problems in most countries. To summarize, the brief involvement of SP may affect tendon healing in an acute injury setting. SP combined with an adequate conjugate can be a regenerative therapeutic option in osteoarthritis. The NK1R antagonist is a promising agent for tendinopathy, rheumatoid arthritis, and osteoarthritis. Research on the SP-NK1R pathway will be helpful for developing novel drugs for osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.